Weekly Analysts’ Ratings Updates for Henry Schein (HSIC)

Henry Schein (NASDAQ: HSIC) recently received a number of ratings updates from brokerages and research firms:

• 5/6/2026 – Henry Schein had its “neutral” rating reaffirmed by UBS Group AG. They now have a $85.00 price target on the stock, down from $87.00.
• 5/6/2026 – Henry Schein was given a new $97.00 price target by Robert W. Baird.
• 5/6/2026 – Henry Schein had its price target lowered by Mizuho from $88.00 to $82.00. They now have a “neutral” rating on the stock.
• 5/4/2026 – Henry Schein had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 4/26/2026 – Henry Schein was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 4/24/2026 – Henry Schein had its “underweight” rating reaffirmed by Morgan Stanley. They now have a $64.00 price target on the stock, up from $61.00.
• 4/18/2026 – Henry Schein was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 4/16/2026 – Henry Schein is now covered by BTIG Research. They set a “neutral” rating on the stock.
• 4/15/2026 – Henry Schein is now covered by Citigroup Inc.. They set a “buy” rating and a $100.00 price target on the stock.
• 4/15/2026 – Henry Schein is now covered by Citigroup Inc.. They set a “buy” rating and a $100.00 price target on the stock.

Insider Buying and Selling at Henry Schein

In related news, Director Kurt P. Kuehn sold 2,844 shares of the stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total transaction of $224,562.24. Following the sale, the director owned 15,420 shares of the company’s stock, valued at approximately $1,217,563.20. This represents a 15.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mark E. Mlotek sold 5,925 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total value of $478,740.00. Following the sale, the executive vice president directly owned 80,554 shares in the company, valued at $6,508,763.20. This trade represents a 6.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 105,911 shares of company stock worth $8,574,982 in the last three months. 0.89% of the stock is currently owned by corporate insiders.

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.